CapyFin

Calendar Reports Pricing

Search for a symbol...

Loading...

CapyFin Real-time Earnings Reports.

Products

Earnings
API

Get in Touch

Contact Us
X (Twitter)
LinkedIn

Resources

Privacy Policy
Terms of Service
Sign Up
Sign In

© 2026 CapyFin. All rights reserved.

Disclaimer: CapyFin provides financial data and AI analysis for informational purposes only and does not provide investment advice or recommendations. Real-time data and AI outputs may be inaccurate, incomplete, delayed, or contain errors or hallucinations. Investing involves risk, including loss of principal. The service is provided “as is” and we disclaim liability to the fullest extent permitted by law. See our Terms of Service and Privacy Policy.

Summit Therapeutics (SMMT) Financial Analysis | CapyFin

Summit Therapeutics

SMMT · NASDAQ🇺🇸

Earnings Dividends Seasonality Metrics

Reported earnings about 1 month ago

Previous year: $866

Previous year: -$0.07

GAAP R&D Expenses

Previous year: $5.39M

GAAP G&A Expenses

Previous year: $7.58M

Cash and Equivalents

Previous year: $649M

Previous year: $5.2M

Previous year: $664M

Loading...

Summit Therapeutics

Unlock previous datapoints

Summit Therapeutics

Unlock previous datapoints

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Key Statistics

Market Cap

$11.6B

P/E Ratio

-38.68

Sector

N/A

Industry

N/A

52-Week High

$36.6

52-Week Low

$13.8

GAAP R&D Expenses

$24.8M

GAAP G&A Expenses

$11.6M